EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
Resmetirom and semaglutide are recommended for treating non-cirrhotic MASH with fibrosis stages 2-3, with tailored use based on patient profiles and comorbidities.
- Why it matters: Effective management of MASH is crucial to prevent serious liver-related outcomes and cardiometabolic complications, yet optimal pharmacotherapy strategies are still evolving.
- What they did: The guidance reviews the use of resmetirom and semaglutide, including patient selection, treatment initiation, monitoring, and discontinuation, based on non-invasive fibrosis assessments and individual risk factors.
- The result: Implementing these targeted therapies alongside lifestyle and comorbidity management can improve patient outcomes, though long-term benefits and safety in cirrhotic MASH require further study.